CanSino Biologics to Use Reserves to Offset Accumulated 1.45 Billion Yuan Losses; Shares Gain 3%
MT Newswires Live
Nov 10
CanSino Biologics (HKG:6185) said it plans to use its capital and surplus reserves to fully offset accumulated losses of 1.45 billion yuan as of Dec. 31, 2024, according to a Nov. 7 Hong Kong bourse filing.
Shares of the firm rose 3% in Monday's midday trade.
The plan calls for using 118.4 million yuan of surplus reserves and 1.33 billion yuan of capital reserves, both derived from share premiums, to eliminate the parent company's accumulated losses.
After the adjustment, CanSino's surplus reserve will fall to zero, while its capital reserve will decline to 5.24 billion yuan.
The proposal, approved by the board, will be subject to shareholder approval at an upcoming extraordinary general meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.